Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | GPR183 | P32249 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16614489 | 0.86 | GPR183 (0.65) | GPR183ALDH1A1LMNATP53HPGD | |
| SCHEMBL16599161 | 0.86 | GPR183 (0.65) | MAPTGPR183ALDH1A1LMNATP53 | |
| SCHEMBL16599159 | 0.86 | GPR183 (0.65) | MAPTGPR183ALDH1A1LMNATP53 | |
| SCHEMBL16598979 | 0.80 | NPC1 (0.66) | MAPTGPR183NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16598631 | 0.80 | NPC1 (0.66) | MAPTGPR183NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1588280 | 0.79 | MAPT (0.74) | MAPTGPR183ALDH1A1LMNATP53 | |
| SCHEMBL1588282 | 0.79 | MAPT (0.74) | MAPTGPR183ALDH1A1LMNATP53 | |
| SCHEMBL11479552 | 0.79 | MAPT (0.74) | MAPTGPR183ALDH1A1LMNATP53 | |
| SCHEMBL11479548 | 0.79 | MAPT (0.74) | MAPTGPR183ALDH1A1LMNATP53 | |
| SCHEMBL17954044 | 0.75 | GPR183 (0.88) | MAPTGPR183ALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214951-A1 | EBI2 MODULATORS | BIRC2, HAVCR2, MAVS | MAPT 3773/4885GPR183 22/4885ALDH1A1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.